Ascletis Pharma Reports Positive Phase Ib Results for ASC47 and FDA Clearance for Combination Study

Ascletis Pharma, Inc. ( (HK:1672) ) has provided an update.

Ascletis Pharma Inc. announced positive results from its Phase Ib studies of ASC47, a weight loss drug candidate, demonstrating a significant half-life and good tolerability in both healthy subjects and patients with obesity. The U.S. FDA has cleared the IND application for ASC47 in combination with semaglutide, potentially enhancing the company’s positioning in the obesity treatment market by offering a promising new therapy option.

More about Ascletis Pharma, Inc.

Ascletis Pharma Inc. operates in the pharmaceutical industry, focusing on developing innovative therapies for various health conditions. The company specializes in adipose-targeted muscle-preserving weight loss drugs, with a market focus on obesity treatment.

YTD Price Performance: 140.86%

Average Trading Volume: 5,692,404

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$7.02B

See more insights into 1672 stock on TipRanks’ Stock Analysis page.